

Massimo Libra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5857015/publications.pdf>

Version: 2024-02-01

304
papers

17,927
citations

13865

67
h-index

17105

122
g-index

313
all docs

313
docs citations

313
times ranked

27600
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Dietary Polyphenols on Vascular Health and Hypertension: Current Evidence and Mechanisms of Action. <i>Nutrients</i> , 2022, 14, 545.	4.1	58
2	Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer. <i>Cancers</i> , 2022, 14, 922.	3.7	5
3	The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K/Akt Pathways. <i>Pharmaceutics</i> , 2022, 14, 590.	4.5	11
4	Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	17
5	B cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma. <i>Hematological Oncology</i> , 2022, , .	1.7	4
6	Co-Occurrence of Interleukin-6 Receptor Asp358Ala Variant and High Plasma Levels of IL-6: An Evidence of IL-6 Trans-Signaling Activation in Deep Vein Thrombosis (DVT) Patients. <i>Biomolecules</i> , 2022, 12, 681.	4.0	6
7	The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. <i>Antioxidants</i> , 2022, 11, 1195.	5.1	8
8	Chronic Pesticide Exposure in Farm Workers Is Associated with the Epigenetic Modulation of hsa-miR-199a-5p. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7018.	2.6	3
9	Dietary phytoestrogens and biomarkers of their intake in relation to cancer survival and recurrence: a comprehensive systematic review with meta-analysis. <i>Nutrition Reviews</i> , 2021, 79, 42-65.	5.8	34
10	Nitric Oxide in Hematological Cancers: Partner or Rival?. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 383-401.	5.4	10
11	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. <i>Advances in Biological Regulation</i> , 2021, 79, 100780.	2.3	6
12	Total Nut, Tree Nut, and Peanut Consumption and Metabolic Status in Southern Italian Adults. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1847.	2.6	12
13	Polyphenol-Rich and Alcoholic Beverages and Metabolic Status in Adults Living in Sicily, Southern Italy. <i>Foods</i> , 2021, 10, 383.	4.3	6
14	Interaction between matrix metalloproteinase-9 (MMP-9) and neutrophil gelatinase-associated lipocalin (NGAL): A recent evolutionary event in primates. <i>Developmental and Comparative Immunology</i> , 2021, 116, 103933.	2.3	3
15	GSK-3 β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. <i>Cells</i> , 2021, 10, 816.	4.1	19
16	Current and innovative methods for the diagnosis of COVID-19 infection (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	4.0	110
17	Serum Extracellular Vesicle-Derived circHIPK3 and circSMARCA5 Are Two Novel Diagnostic Biomarkers for Glioblastoma Multiforme. <i>Pharmaceutics</i> , 2021, 14, 618.	3.8	64
18	Post-Mortem Detection of SARS-CoV-2 RNA in Long-Buried Lung Samples. <i>Diagnostics</i> , 2021, 11, 1158.	2.6	22

#	ARTICLE	IF	CITATIONS
19	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	3.3	17
20	Prognostic Value of the Immunohistochemical Expression of Serine and Arginine-Rich Splicing Factor 1 (SRSF1) in Uveal Melanoma: A Clinico-Pathological and Immunohistochemical Study on a Series of 85 Cases. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 7874.	2.5	3
21	YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8481.	4.1	8
22	Novel Insights into Epigenetic Regulation of IL6 Pathway: In Silico Perspective on Inflammation and Cancer Relationship. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10172.	4.1	29
23	Adherence to the Mediterranean Diet in Maltese Adults. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10.	2.6	23
24	Quality of Life in Women Diagnosed with Breast Cancer after a 12-Month Treatment of Lifestyle Modifications. <i>Nutrients</i> , 2021, 13, 136.	4.1	43
25	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. <i>Advances in Biological Regulation</i> , 2021, , 100840.	2.3	4
26	Abilities of ¹⁷ β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2020, 75, 100672.	2.3	9
27	SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. <i>Food and Chemical Toxicology</i> , 2020, 146, 111769.	3.6	117
28	Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial. <i>PLoS ONE</i> , 2020, 15, e0239803.	2.5	42
29	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. <i>Advances in Biological Regulation</i> , 2020, 78, 100758.	2.3	21
30	Cutaneous melanoma and the immunotherapy revolution (Review). <i>International Journal of Oncology</i> , 2020, 57, 609-618.	3.3	75
31	Droplet Digital PCR Analysis of Liquid Biopsy Samples Unveils the Diagnostic Role of hsa-miR-133a-3p and hsa-miR-375-3p in Oral Cancer. <i>Biology</i> , 2020, 9, 379.	2.8	30
32	Cancer therapy and treatments during COVID-19 era. <i>Advances in Biological Regulation</i> , 2020, 77, 100739.	2.3	30
33	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. <i>Cancers</i> , 2020, 12, 2237.	3.7	71
34	Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity. <i>Cancers</i> , 2020, 12, 2555.	3.7	52
35	Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6446.	4.1	7
36	Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment. <i>Cancers</i> , 2020, 12, 3636.	3.7	23

#	ARTICLE	IF	CITATIONS
37	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. <i>Cells</i> , 2020, 9, 1110.	4.1	146
38	Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma. <i>Cells</i> , 2020, 9, 1151.	4.1	78
39	Association between Nutrient-Based Dietary Patterns and Bladder Cancer in Italy. <i>Nutrients</i> , 2020, 12, 1584.	4.1	11
40	S100A7/Ran-binding protein 9 coevolution in mammals. <i>Immunogenetics</i> , 2020, 72, 155-164.	2.4	1
41	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4687-4695.	2.2	16
42	Association of Viral Infections With Oral Cavity Lesions: Role of SARS-CoV-2 Infection. <i>Frontiers in Medicine</i> , 2020, 7, 571214.	2.6	39
43	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. <i>Aging</i> , 2020, 12, 10194-10210.	3.1	15
44	Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection. <i>International Journal of Molecular Medicine</i> , 2020, 46, 957-964.	4.0	176
45	Droplet digital PCR for the detection and monitoring of <i>Legionella pneumophila</i> . <i>International Journal of Molecular Medicine</i> , 2020, 46, 1777-1782.	4.0	15
46	Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review). <i>International Journal of Oncology</i> , 2020, 58, 145-157.	3.3	55
47	Abstract 4836: Diagnostic and prognostic significance of microRNA modulation in oral cancer. , 2020, , .		0
48	Abstract 4687: Oncogenic role of the transcription factor YY1 and its target Survivin in non-Hodgkin's lymphoma. , 2020, , .		0
49	Abstract 2400: Strong biological bias for ALK intron 19 breakpoints in NSCLC. , 2020, , .		0
50	Contribution of Immunohistochemistry in Revealing S100A7/JAB1 Colocalization in Psoriatic Epidermal Keratinocyte. <i>Methods in Molecular Biology</i> , 2019, 2109, 67-74.	0.9	0
51	Dietary Inflammatory Index in Ageing and Longevity. , 2019, , 71-86.		3
52	Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. <i>Cells</i> , 2019, 8, 863.	4.1	156
53	The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy. <i>Frontiers in Medicine</i> , 2019, 6, 172.	2.6	36
54	The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease. <i>Oncology Reports</i> , 2019, 42, 911-922.	2.6	70

#	ARTICLE	IF	CITATIONS
55	Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. <i>Cells</i> , 2019, 8, 1251.	4.1	53
56	Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling. <i>Brain Sciences</i> , 2019, 9, 221.	2.3	22
57	Current Perspectives in Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1472.	3.7	149
58	Food consumption, meat cooking methods and diet diversity and the risk of bladder cancer. <i>Cancer Epidemiology</i> , 2019, 63, 101595.	1.9	18
59	Cancer-associated stroke: Pathophysiology, detection and management (Review). <i>International Journal of Oncology</i> , 2019, 54, 779-796.	3.3	104
60	<p>Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3171-3179.	2.0	38
61	Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer. <i>Cancers</i> , 2019, 11, 610.	3.7	94
62	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2019, 73, 100633.	2.3	25
63	Flavonoids and bladder cancer risk. <i>Cancer Causes and Control</i> , 2019, 30, 527-535.	1.8	14
64	Prognostic significance of deregulated microRNAs in uveal melanomas. <i>Molecular Medicine Reports</i> , 2019, 19, 2599-2610.	2.4	69
65	EpiMethEx: a tool for large-scale integrated analysis in methylation hotspots linked to genetic regulation. <i>BMC Bioinformatics</i> , 2019, 19, 385.	2.6	6
66	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. <i>Advances in Biological Regulation</i> , 2019, 72, 22-40.	2.3	10
67	Dietary inflammatory index and cancer risk in the elderly: A pooled-analysis of Italian case-control studies. <i>Nutrition</i> , 2019, 63-64, 205-210.	2.4	22
68	Gut Microbiota and Cancer: From Pathogenesis to Therapy. <i>Cancers</i> , 2019, 11, 38.	3.7	378
69	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2019, 71, 172-182.	2.3	34
70	Bladder cancer risk in users of selected drugs for cardiovascular disease prevention. <i>European Journal of Cancer Prevention</i> , 2019, 28, 76-80.	1.3	11
71	Association between dietary inflammatory index and Hodgkin's lymphoma in an Italian case-control study. <i>Nutrition</i> , 2018, 53, 43-48.	2.4	7
72	Metformin influences drug sensitivity in pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2018, 68, 13-30.	2.3	45

#	ARTICLE	IF	CITATIONS
73	Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology, 2018, 52, 1071-1080.	3.3	281
74	Processed Meat and Risk of Renal Cell and Bladder Cancers. Nutrition and Cancer, 2018, 70, 418-424.	2.0	9
75	Metabolic disorders and the risk of nasopharyngeal carcinoma: a case-control study in Italy. European Journal of Cancer Prevention, 2018, 27, 180-183.	1.3	11
76	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals. Advances in Biological Regulation, 2018, 67, 190-211.	2.3	23
77	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Frontiers in Pharmacology, 2018, 9, 1300.	3.5	602
78	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. Frontiers in Pharmacology, 2018, 9, 856.	3.5	68
79	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. Anticancer Research, 2018, 38, 3689-3697.	1.1	32
80	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation, 2018, 69, 16-34.	2.3	27
81	Ageing: from inflammation to cancer. Immunity and Ageing, 2018, 15, 1.	4.2	166
82	Mediterranean Diet and Bladder Cancer Risk in Italy. Nutrients, 2018, 10, 1061.	4.1	30
83	Roles of p53, NF- κ B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation, 2018, 69, 43-62.	2.3	21
84	Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development. Aging, 2018, 10, 1000-1014.	3.1	135
85	Abstract 5305: DNA methylation and gene expression in melanoma: A large-scale integrated analysis. , 2018, , .		0
86	NF- κ B inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma. Oncology Reports, 2017, 37, 737-746.	2.6	70
87	Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial. BMC Cancer, 2017, 17, 69.	2.6	31
88	Adherence to the Mediterranean diet and nasopharyngeal cancer risk in Italy. Cancer Causes and Control, 2017, 28, 89-95.	1.8	77
89	The risk of HCV infection among health-care workers and its association with extrahepatic manifestations. Molecular Medicine Reports, 2017, 15, 3336-3339.	2.4	14
90	The dose-response relationship between tobacco smoking and the risk of lymphomas: a case-control study. BMC Cancer, 2017, 17, 421.	2.6	24

#	ARTICLE	IF	CITATIONS
91	Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case-control study. <i>Cancer Causes and Control</i> , 2017, 28, 791-799.	1.8	15
92	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. <i>Advances in Biological Regulation</i> , 2017, 65, 77-88.	2.3	39
93	Family history of cancer and the risk of bladder cancer: A case-control study from Italy. <i>Cancer Epidemiology</i> , 2017, 48, 29-35.	1.9	21
94	Identification of novel chemotherapeutic strategies for metastatic uveal melanoma. <i>Scientific Reports</i> , 2017, 7, 44564.	3.3	44
95	Associations of dietary carbohydrates, glycaemic index and glycaemic load with risk of bladder cancer: a case-control study. <i>British Journal of Nutrition</i> , 2017, 118, 722-729.	2.3	20
96	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN β Signaling. <i>Cancer Research</i> , 2017, 77, 4562-4566.	0.9	39
97	Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes. <i>Journal of Cellular Physiology</i> , 2017, 232, 1144-1150.	4.1	13
98	Dietary Inflammatory Index and Risk of Bladder Cancer in a Large Italian Case-control Study. <i>Urology</i> , 2017, 100, 84-89.	1.0	41
99	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. <i>Advances in Biological Regulation</i> , 2017, 63, 32-48.	2.3	36
100	Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer. <i>Frontiers in Pharmacology</i> , 2017, 8, 603.	3.5	96
101	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 259-269.	2.7	37
102	Epigenetic alterations and occupational exposure to benzene, fibers, and heavy metals associated with tumor development. <i>Molecular Medicine Reports</i> , 2017, 15, 3366-3371.	2.4	25
103	Immunological effects of occupational exposure to lead. <i>Molecular Medicine Reports</i> , 2017, 15, 3355-3360.	2.4	80
104	Absence of t(14;18) chromosome translocation in agricultural workers after short-term exposure to pesticides. <i>Molecular Medicine Reports</i> , 2017, 15, 3379-3382.	2.4	28
105	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. <i>Aging</i> , 2017, 9, 1477-1536.	3.1	168
106	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. <i>Oncotarget</i> , 2017, 8, 14221-14250.	1.8	86
107	Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. <i>Oncotarget</i> , 2017, 8, 71528-71535.	1.8	11
108	The miR-200 family in ovarian cancer. <i>Oncotarget</i> , 2017, 8, 66629-66640.	1.8	56

#	ARTICLE	IF	CITATIONS
109	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , 2017, 8, 76525-76557.	1.8	17
110	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. <i>Oncotarget</i> , 2017, 8, 113013-113033.	1.8	8
111	Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. <i>PLoS ONE</i> , 2016, 11, e0152104.	2.5	50
112	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. <i>Aging</i> , 2016, 8, 933-944.	3.1	67
113	Low levels of inflammation and the absence of subclinical atherosclerosis in rheumatoid arthritis. <i>Molecular Medicine Reports</i> , 2016, 13, 3521-3524.	2.4	7
114	Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells. <i>Oncology Letters</i> , 2016, 12, 3363-3367.	1.8	24
115	Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2016, 11, 3-8.	1.8	10
116	Computational modeling in melanoma for novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 609-621.	5.0	15
117	Effects of mutations in Wnt/ β -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2942-2976.	4.1	137
118	Overexpression of the Transcription Factor Yin Yang 1 in Non-Hodgkin Lymphoma is associated with Chemo-Immune Resistance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S119-S120.	0.4	2
119	Increased Risk of Nasopharyngeal Carcinoma with Increasing Levels of Diet-Associated Inflammation in an Italian Case—Control Study. <i>Nutrition and Cancer</i> , 2016, 68, 1123-1130.	2.0	24
120	Fluoro-edenite and carbon nanotubes: The health impact of “asbestos-like” fibres. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 21-27.	1.8	23
121	Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. <i>Oncology Letters</i> , 2016, 11, 1021-1025.	1.8	53
122	Dietary water intake and bladder cancer risk: An Italian case—control study. <i>Cancer Epidemiology</i> , 2016, 45, 151-156.	1.9	15
123	Occupational exposure to carcinogens: Benzene, pesticides and fibers. <i>Molecular Medicine Reports</i> , 2016, 14, 4467-4474.	2.4	80
124	Occupational exposure to pesticides as a possible risk factor for the development of chronic diseases in humans. <i>Molecular Medicine Reports</i> , 2016, 14, 4475-4488.	2.4	116
125	Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. <i>Infectious Agents and Cancer</i> , 2016, 11, 27.	2.6	38
126	NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. <i>Cell Death and Disease</i> , 2016, 7, e2269-e2269.	6.3	94

#	ARTICLE	IF	CITATIONS
127	The therapeutic potential of mTOR inhibitors in breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1189-1212.	2.4	93
128	Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). <i>International Journal of Oncology</i> , 2016, 48, 869-885.	3.3	302
129	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. <i>Tumor Biology</i> , 2016, 37, 9855-9863.	1.8	15
130	Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 483-489.	4.1	29
131	Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease. <i>Angiology</i> , 2016, 67, 870-874.	1.8	32
132	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 438-448.	4.1	79
133	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. <i>Oncotarget</i> , 2016, 7, 72758-72766.	1.8	73
134	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , 2016, 22, 2358-2388.	1.9	34
135	Yin Yang 1 (YY1) Acting Primarily As an Oncogene and Rarely As a Tumor Suppressor in Distinct Hematological Malignancies: Prognostic and Therapeutic Implications. <i>Blood</i> , 2016, 128, 5122-5122.	1.4	0
136	Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. <i>BMC Cancer</i> , 2015, 15, 720.	2.6	42
137	Regular aspirin use and nasopharyngeal cancer risk: A case-control study in Italy. <i>Cancer Epidemiology</i> , 2015, 39, 545-547.	1.9	10
138	Diabetes mellitus and the risk of bladder cancer: an Italian case-control study. <i>British Journal of Cancer</i> , 2015, 113, 127-130.	6.4	15
139	FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: a pilot study. <i>Future Oncology</i> , 2015, 11, 35-37.	2.4	26
140	Malignant melanoma in elderly patients: biological, surgical and medical issues. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 101-108.	2.4	27
141	Notch4 and MHC class II polymorphisms contribute to HCV-related benign and malignant lymphoproliferative diseases. <i>Digestive and Liver Disease</i> , 2015, 47, e14.	0.9	0
142	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. <i>Advances in Biological Regulation</i> , 2015, 59, 65-81.	2.3	121
143	P0752 : NOTCH4 and MHC class II polymorphisms contribute to HCV-related benign and malignant lymphoproliferative diseases. <i>Journal of Hepatology</i> , 2015, 62, S611.	3.7	0
144	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. <i>Leukemia Research</i> , 2015, 39, 1088-1095.	0.8	25

#	ARTICLE	IF	CITATIONS
145	Different pediatric brain tumors are associated with different gene expression profiling. <i>Acta Histochemica</i> , 2015, 117, 477-485.	1.8	31
146	Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. <i>PLoS ONE</i> , 2015, 10, e0117420.	2.5	54
147	Coffee, Tea, Cola, and Bladder Cancer Risk: Dose and Time Relationships. <i>Urology</i> , 2015, 86, 1179-1184.	1.0	18
148	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. <i>Advances in Biological Regulation</i> , 2015, 57, 75-101.	2.3	100
149	Increased Levels of NF- κ B-Dependent Markers in Cancer-Associated Deep Venous Thrombosis. <i>PLoS ONE</i> , 2015, 10, e0132496.	2.5	45
150	Abstract 4304: MMP-9 as a marker of response to treatment with B-Raf inhibitors in cutaneous melanoma. , 2015, , .		0
151	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. <i>Oncotarget</i> , 2014, 5, 1576-1594.	1.8	91
152	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , 2014, 5, 4603-4650.	1.8	231
153	GSK-3 as potential target for therapeutic intervention in cancer. <i>Oncotarget</i> , 2014, 5, 2881-2911.	1.8	407
154	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. <i>EMBO Molecular Medicine</i> , 2014, 6, 295-295.	6.9	3
155	Multifaceted roles of GSK-3 and Wnt/ β -catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. <i>Leukemia</i> , 2014, 28, 15-33.	7.2	208
156	Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST. <i>International Journal of Colorectal Disease</i> , 2014, 29, 639-640.	2.2	5
157	Diverse roles of GSK-3: Tumor promoter and tumor suppressor, target in cancer therapy. <i>Advances in Biological Regulation</i> , 2014, 54, 176-196.	2.3	80
158	Duration and intensity of tobacco smoking and the risk of papillary and non-papillary transitional cell carcinoma of the bladder. <i>Cancer Causes and Control</i> , 2014, 25, 1151-1158.	1.8	25
159	Molecular screening in Sicilian families with hereditary non-poliposis colorectal cancer (H.N.P.C.C.) syndrome: Identification of a novel mutation in MSH2 gene. <i>International Journal of Surgery</i> , 2014, 12, S120-S124.	2.7	1
160	Molecular analysis of the APC gene in Sicilian patients with familial adenomatous polyposis (F.A.P.). <i>International Journal of Surgery</i> , 2014, 12, S125-S129.	2.7	3
161	Targeting breast cancer initiating cells: Advances in breast cancer research and therapy. <i>Advances in Biological Regulation</i> , 2014, 56, 81-107.	2.3	32
162	Cancer risk evaluation: Preliminary analysis of inflammatory biomarkers in farmers exposed to zoonotic agents. <i>International Journal of Infectious Diseases</i> , 2014, 21, 185.	3.3	0

#	ARTICLE	IF	CITATIONS
163	Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure. <i>Oncology Reports</i> , 2014, 31, 1079-1082.	2.6	44
164	Emerging targeted therapies for melanoma treatment (Review). <i>International Journal of Oncology</i> , 2014, 45, 516-524.	3.3	39
165	Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 112, 63-69.	2.5	14
166	IL-6-174 G>C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. <i>Cytokine</i> , 2013, 62, 64-69.	3.2	27
167	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. <i>EMBO Molecular Medicine</i> , 2013, 5, 707-722.	6.9	49
168	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
169	Raf kinase inhibitor protein (RKIP) and phospho-RKIP expression in melanomas. <i>Acta Histochemica</i> , 2013, 115, 795-802.	1.8	20
170	Red meat and cancer risk in a network of case-control studies focusing on cooking practices. <i>Annals of Oncology</i> , 2013, 24, 3107-3112.	1.2	64
171	A tailored health surveillance program unveils a case of MALT lymphoma in an HCV-positive health-care worker. <i>Oncology Letters</i> , 2013, 5, 651-654.	1.8	8
172	Abstract 4074: Transcription factors involved in the genesis and progression of cancer differently modulated by transforming growth factor-beta3 (TGF-Beta3) in prostate cell lines.. , 2013, , .		0
173	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). <i>International Journal of Oncology</i> , 2012, 40, 639-44.	3.3	81
174	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , 2012, 11, 4447-4461.	2.6	22
175	The tumor microenvironment in hepatocellular carcinoma (Review). <i>International Journal of Oncology</i> , 2012, 40, 1733-47.	3.3	111
176	microRNAs and thyroid cancer: Biological and clinical significance. <i>International Journal of Molecular Medicine</i> , 2012, 30, 991-999.	4.0	38
177	Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs. <i>Current Drug Delivery</i> , 2012, 9, 17-29.	1.6	22
178	Breast cancer risk in women treated with augmentation mammoplasty (Review). <i>Oncology Reports</i> , 2012, 28, 3-7.	2.6	25
179	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (Review). <i>Molecular Medicine Reports</i> , 2012, 6, 687-694.	2.4	25
180	Dietary intakes of carotenoids and other nutrients in the risk of nasopharyngeal carcinoma: a case-control study in Italy. <i>British Journal of Cancer</i> , 2012, 107, 1580-1583.	6.4	22

#	ARTICLE	IF	CITATIONS
181	Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. <i>Cytokine</i> , 2012, 59, 294-298.	3.2	33
182	Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review). <i>Oncology Reports</i> , 2012, 28, 418-428.	2.6	36
183	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 1784-1795.	1.9	39
184	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.	1.8	279
185	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.	1.8	244
186	Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. <i>Oncotarget</i> , 2012, 3, 882-892.	1.8	107
187	Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. <i>Oncotarget</i> , 2012, 3, 1236-1245.	1.8	13
188	Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.	1.8	41
189	Molecular-Targeted Therapy for Melanoma. , 2012, , 265-279.		0
190	Abstract 4197: Discovering FUS-CHOP targets: A Chip-Seq approach. , 2012, , .		0
191	Modulation of YY1 and p53 expression by transforming growth factor- β 3 in prostate cell lines. <i>Cytokine</i> , 2011, 56, 403-410.	3.2	12
192	Understanding rituximab function and resistance: implications for tailored therapy. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 770.	3.0	33
193	Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients. <i>International Journal of Molecular Medicine</i> , 2011, 28, 437-42.	4.0	4
194	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. <i>Leukemia</i> , 2011, 25, 1064-1079.	7.2	190
195	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. <i>Leukemia</i> , 2011, 25, 1080-1094.	7.2	232
196	Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. <i>Oral Oncology</i> , 2011, 47, 541-545.	1.5	70
197	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. <i>Journal of Cellular Physiology</i> , 2011, 226, 2762-2781.	4.1	147
198	Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). <i>Molecular Medicine Reports</i> , 2011, 4, 203-8.	2.4	24

#	ARTICLE	IF	CITATIONS
199	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. <i>Cell Cycle</i> , 2011, 10, 3003-3015.	2.6	77
200	Genetic profiling and ovarian cancer therapy (Review). <i>Molecular Medicine Reports</i> , 2011, 4, 771-7.	2.4	25
201	Characterization of human melanoma cell lines and melanocytes by proteome analysis. <i>Cell Cycle</i> , 2011, 10, 2924-2936.	2.6	34
202	Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2011, 2, 179-188.	0.1	14
203	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.	3.1	520
204	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.	1.8	509
205	Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy. <i>Oncotarget</i> , 2011, 2, 538-550.	1.8	73
206	Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. <i>Oncotarget</i> , 2011, 2, 1265-1278.	1.8	61
207	Abstract 5263: Osteopontin/matrixmetalloproteinasis pathway activation in head and neck cancer. , 2011, , .		0
208	Abstract 332: B-Raf mutations are associated with a worse outcome in ovarian cancer. , 2011, , .		0
209	New Perspectives in HCV Therapy: Entry Inhibitors. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2010, 5, 181-194.	0.8	2
210	Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. <i>Cell Cycle</i> , 2010, 9, 557-563.	2.6	48
211	Extrahepatic disorders of HCV infection: A distinct entity of B-cell neoplasia?. <i>International Journal of Oncology</i> , 2010, 36, 1331-40.	3.3	36
212	Prevalence of hepatitis C virus infection among health-care workers: A 10-year survey. <i>Molecular Medicine Reports</i> , 2010, 3, 561-4.	2.4	11
213	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. <i>Free Radical Biology and Medicine</i> , 2010, 48, 1090-1099.	2.9	10
214	Dehydroxymethylepoxyquinomicin, a novel nuclear factor- κ B inhibitor, prevents inflammatory injury induced by interferon- γ and histamine in NCTC-2544 keratinocytes. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 679-683.	1.9	7
215	HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. <i>Tissue Antigens</i> , 2010, 75, 127-135.	1.0	22
216	Dehydroxymethylepoxyquinomicin Inhibits Expression and Production of Inflammatory Mediators in Interleukin-1 β -induced Human Chondrocytes. <i>Cellular Physiology and Biochemistry</i> , 2010, 25, 543-550.	1.6	6

#	ARTICLE	IF	CITATIONS
217	The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. <i>Cell Cycle</i> , 2010, 9, 1781-1791.	2.6	110
218	Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. <i>Cell Cycle</i> , 2010, 9, 1629-1638.	2.6	41
219	Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. <i>Cell Cycle</i> , 2010, 9, 1839-1846.	2.6	29
220	Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. <i>International Journal of Oncology</i> , 2010, 37, 1167-76.	3.3	12
221	Emerging MEK inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 203-223.	2.4	54
222	Clinical Significance of YY1 Overexpression in Human Hematopoietic Malignancies. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2010, 1, 127-139.	0.1	0
223	Computational Evaluation of Yin Yang 1 Transcript Levels in the Spectrum of B-cell Neoplasia. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2010, 1, 115-125.	0.1	1
224	COMMENTARY. Diagnostic and Prognostic roles of YY1. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2010, 1, 153-154.	0.1	0
225	Rationale for Targeting of YY1 in Drug-resistant Leukemias. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2010, 1, 65-79.	0.1	1
226	BRAF and RKIP aberrations in actinic keratosis and non-melanoma skin cancers. <i>Cell Cycle</i> , 2009, 8, 1305-1307.	2.6	1
227	The involvement of the transcription factor Yin Yang 1 in cancer development and progression. <i>Cell Cycle</i> , 2009, 8, 1367-1372.	2.6	123
228	Emerging Raf inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 633-648.	2.4	33
229	PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches. <i>Cell Cycle</i> , 2009, 8, 1352-1358.	2.6	173
230	Melanoma: Molecular pathogenesis and emerging target therapies (Review). <i>International Journal of Oncology</i> , 2009, 34, 1481-9.	3.3	64
231	Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. <i>Leukemia</i> , 2009, 23, 25-42.	7.2	174
232	The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1169-1178.	4.1	38
233	Uterine cervical carcinoma: Role of matrix metalloproteinases (Review). <i>International Journal of Oncology</i> , 2009, 34, 897-903.	3.3	103
234	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008, 48, 113-135.	2.6	20

#	ARTICLE	IF	CITATIONS
235	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. <i>Leukemia</i> , 2008, 22, 2080-2090.	7.2	70
236	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. <i>Leukemia</i> , 2008, 22, 686-707.	7.2	337
237	Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. <i>Leukemia</i> , 2008, 22, 708-722.	7.2	222
238	Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. <i>Oncogene</i> , 2008, 27, 4086-4095.	5.9	147
239	In vitro inhibition of enterobacteria-reactive CD4+CD25 ^{hi} T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. <i>European Journal of Pharmacology</i> , 2008, 586, 313-321.	3.5	14
240	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. <i>Journal of Hepatology</i> , 2008, 49, 170-174.	3.7	31
241	Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid ⁺ nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. <i>Nitric Oxide - Biology and Chemistry</i> , 2008, 19, 177-183.	2.7	26
242	Akt as a therapeutic target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1139-1165.	3.4	125
243	Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 510-520.	4.1	68
244	Targeting prostate cancer based on signal transduction and cell cycle pathways. <i>Cell Cycle</i> , 2008, 7, 1745-1762.	2.6	89
245	Activation of the Osteopontin/Matrix Metalloproteinase-9 Pathway Correlates with Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2008, 14, 7470-7480.	7.0	99
246	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
247	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Signaling and p53 Pathways on Apoptosis, Drug Resistance and Therapeutic Sensitivity of Early Hematopoietic Precursor Cells. <i>Blood</i> , 2008, 112, 503-503.	1.4	0
248	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). <i>Molecular Medicine Reports</i> , 2008, 1, 139-60.	2.4	5
249	Breast cancer: Molecular basis and therapeutic strategies (Review). <i>Molecular Medicine Reports</i> , 2008, 1, 451-8.	2.4	16
250	The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation. <i>Cancer Research</i> , 2007, 67, 4287-4294.	0.9	87
251	Inflammatory status in patients with chronic renal failure: The role of PTX3 and pro-inflammatory cytokines. <i>International Journal of Molecular Medicine</i> , 2007, 20, 471.	4.0	19
252	Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. <i>Digestive and Liver Disease</i> , 2007, 39, S65-S71.	0.9	20

#	ARTICLE	IF	CITATIONS
253	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 1263-1284.	4.1	1,858
254	Role of the HLA Class II: HCV-Related Disorders. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 308-318.	3.8	19
255	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , 2007, 47, 64-103.	2.6	77
256	An Italian multicenter controlled study of HCV-related malignancies: Role of the HLA class II. <i>Digestive and Liver Disease</i> , 2006, 38, S30.	0.9	1
257	Analysis of interleukin (IL)-1 β IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. <i>Oncology Reports</i> , 2006, 15, 1305.	2.6	7
258	Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent. <i>International Journal of Molecular Medicine</i> , 2006, 17, 539.	4.0	2
259	Gene expression in mouse spermatogenesis during ontogenesis. <i>International Journal of Molecular Medicine</i> , 2006, 17, 523.	4.0	3
260	A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin. <i>Modern Pathology</i> , 2006, 19, 299-306.	5.5	44
261	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. <i>Advances in Enzyme Regulation</i> , 2006, 46, 249-279.	2.6	584
262	Analysis of TIMP-1 Gene Polymorphisms in Italian Sclerodermic Patients. <i>Journal of Clinical Laboratory Analysis</i> , 2006, 20, 173-176.	2.1	21
263	Reply. <i>Hepatology</i> , 2006, 43, 1167-1168.	7.3	2
264	Oral Etoposide in Elderly Patients with Advanced Non Small Cell Lung Cancer: A Clinical and Pharmacological Study. <i>Journal of Chemotherapy</i> , 2006, 18, 188-191.	1.5	5
265	Detection of <i>BRAF</i> gene mutation in primary choroidal melanoma tissue. <i>Cancer Biology and Therapy</i> , 2006, 5, 225-227.	3.4	34
266	Long pentraxin 3: A marker of inflammation in untreated psoriatic patients. <i>International Journal of Molecular Medicine</i> , 2006, 18, 415.	4.0	24
267	Absence of BRAF Gene Mutation in Non-Melanoma Skin Tumors. <i>Cell Cycle</i> , 2006, 5, 968-970.	2.6	27
268	Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. <i>Journal of Clinical Pathology</i> , 2006, 59, 211-215.	2.0	68
269	Analysis of interleukin (IL)-1 β IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. <i>Oncology Reports</i> , 2006, 15, 1305-8.	2.6	16
270	HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. <i>Hepatology</i> , 2005, 42, 1019-1027.	7.3	25

#	ARTICLE	IF	CITATIONS
271	Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. <i>Journal of Pathology</i> , 2005, 206, 87-91.	4.5	29
272	Hepatitis C virus (HCV) infection and lymphoproliferative disorders. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2460.	3.0	25
273	Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. <i>Vascular Medicine</i> , 2005, 10, 1-6.	1.5	113
274	JH6 Gene Usage among HCV-Associated MALT Lymphomas Harboring t(14;18) Translocation. <i>Journal of Immunology</i> , 2005, 174, 3839.1-3839.	0.8	7
275	Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. <i>Cancer Biology and Therapy</i> , 2005, 4, 1192-1194.	3.4	27
276	Two targets are better than one, Promising combination therapy to treat breast cancer. <i>Cancer Biology and Therapy</i> , 2005, 4, 1190-1191.	3.4	1
277	Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. <i>International Journal of Oncology</i> , 2005, 26, 945.	3.3	3
278	Bovine seminal ribonuclease is cytotoxic for both malignant and normal telomerase-positive cells. <i>International Journal of Oncology</i> , 2005, 27, 1071.	3.3	4
279	Analysis of BRAF Mutation in Primary and Metastatic Melanoma. <i>Cell Cycle</i> , 2005, 4, 1382-1384.	2.6	91
280	Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. <i>International Journal of Oncology</i> , 2005, 26, 945-50.	3.3	3
281	Analysis of hepatitis C virus infection among health-care workers: an observational study. <i>Minerva Gastroenterologica E Dietologica</i> , 2005, 51, 255-9.	2.2	7
282	Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. <i>BMC Cancer</i> , 2004, 4, 11.	2.6	28
283	D1S80 VNTR locus genotypes in a population of Southeastern Sicily: Distribution and genetic disequilibrium. <i>American Journal of Human Biology</i> , 2004, 16, 91-94.	1.6	1
284	Second Primary Lymphoma or Recurrence: A Dilemma Solved by VDJ Rearrangement Analysis. <i>Leukemia and Lymphoma</i> , 2004, 45, 1539-1543.	1.3	20
285	Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. <i>Haematologica</i> , 2004, 89, 873-4.	3.5	17
286	Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue. <i>Leukemia</i> , 2003, 17, 1433-1436.	7.2	22
287	Solid pseudopapillary tumour of the pancreas. <i>Lancet Oncology</i> , The, 2003, 4, 255-256.	10.7	54
288	All trans retinoic acid sensitizes colon cancer cells to hyperthermia cytotoxic effects. <i>International Journal of Oncology</i> , 2003, 23, 181.	3.3	1

#	ARTICLE	IF	CITATIONS
289	Cisplatin may be a Valid Alternative Approach in Ovarian Carcinoma with Carboplatin Hypersensitivity. Report of Three Cases. <i>Tumori</i> , 2003, 89, 311-313.	1.1	12
290	Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution. <i>Tumori</i> , 2003, 89, 400-404.	1.1	6
291	Methylenetetrahydrofolate reductase 677 C->T polymorphism and risk of proximal colon cancer in north Italy. <i>Clinical Cancer Research</i> , 2003, 9, 743-8.	7.0	52
292	Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 855-856.	0.9	10
293	Expression of Cyclin-Dependent Kinase Inhibitor p27Kip1 in AIDS-Related Diffuse Large-Cell Lymphomas Is Associated with Epstein-Barr Virus-Encoded Latent Membrane Protein 1. <i>American Journal of Pathology</i> , 2002, 161, 163-171.	3.8	11
294	Prognostic factors in soft tissue sarcomas: a study of 395 patients. <i>European Journal of Surgical Oncology</i> , 2002, 28, 153-164.	1.0	105
295	Carboplatin in Elderly Patients. <i>Tumori</i> , 2002, 88, S35-S36.	1.1	0
296	Lack of Hcv Infection in Malignant, Cells Refutes the Hypothesis of a Direct Transforming Action of the Virus in the Pathogenesis of Hcv-Associated B-Cell NHLs. <i>Tumori</i> , 2002, 88, 400-406.	1.1	21
297	Differentiation between non-Hodgkin's lymphoma recurrence and second primary lymphoma by VDJ rearrangement analysis. <i>British Journal of Haematology</i> , 2002, 118, 809-812.	2.5	14
298	Long term follow up of 50 patients with metastatic renal cell carcinoma treated with high dose i.v. interleukin. 2. <i>European Journal of Cancer</i> , 1999, 35, S358.	2.8	0
299	Expression of ornithine decarboxylase gene in elderly human monocytes. <i>Archives of Gerontology and Geriatrics</i> , 1994, 18, 141-147.	3.0	1
300	Mineral fiber-mediated activation of phosphoinositide-specific phospholipase c in human bronchoalveolar carcinoma-derived alveolar epithelial A549 cells. <i>International Journal of Oncology</i> , 1992, 34, 371.	3.3	3
301	Breast cancer: Molecular basis and therapeutic strategies (Review). <i>Molecular Medicine Reports</i> , 0, , .	2.4	6
302	Benefits of using probiotics as adjuvants in anticancer therapy (Review). <i>World Academy of Sciences Journal</i> , 0, , .	0.6	18
303	Quantitative evaluation of partial deletions of the DAZ gene cluster. <i>International Journal of Molecular Medicine</i> , 0, , .	4.0	2
304	Risk analysis of colorectal cancer in women with endometrial carcinoma. <i>Molecular Medicine Reports</i> , 0, , .	2.4	2